Raymond James Maintains Strong Buy Rating for Mirum Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has maintained its Strong Buy rating for Mirum Pharmaceuticals (NASDAQ:MIRM) and increased its price target from $81.00 to $82.00. Mirum Pharmaceuticals' shares are currently trading at $27.23, up 0.33% over the last 24 hours. The new price target represents a potential increase of 201.14% from the current share price.
July 18, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James' maintained Strong Buy rating and increased price target for Mirum Pharmaceuticals could potentially drive the stock price up in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The maintained Strong Buy rating indicates that Raymond James continues to have high confidence in Mirum Pharmaceuticals' performance. The raised price target suggests that they expect the stock to significantly outperform its current price in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100